News Archive

READING, UK and BEDMINSTER, NJ, 30 June 2011
FDA approves Lazanda® – first Fentanyl nasal spray – for the management of breakthrough pain in cancer patients

READING, UK, 17 January 2011
New Treatment for Breakthrough Cancer Pain Accepted for Use in Scotland

READING, UK and BEDMINSTER, NJ, 12 October 2010
Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray

READING, UK and BEDMINSTER, NJ, 04 October 2010
Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray

READING, UK, 1 September 2010
Archimedes Pharma Received European Marketing Authorisation for PecFent^®
PecFent^® authorized for marketing in European Union countries for the treatment of breakthrough cancer pain

READING, UK and BEDMINSTER, NJ, 19 August 2010
Archimedes Pharma US announces new US Headquarters in Bedminster, New Jersey
Actively recruiting top talent to support US market penetration

READING, UK, 25 June 2010
Archimedes Pharma Receives CHMP Positive Opinion for PecFent^®
PecFent^® authorized for marketing in European Union countries for the treatment of breakthrough cancer pain

READING, UK, 02 March 2010
Archimedes Pharma Announces Major Fundraising of £65 million
Appoints new Chief Executive Officer to accelerate growth of transatlantic business

PecFent^®, Lazanda^®, PecSys^®, and ChiSys^® are registered trademarks of Archimedes Development Ltd.